SeaSpine’s Ventura NanoMetalene Implant Expands to Larger Range of Posterior Procedures

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced the portfolio expansion of the Ventura NanoMetalene posterior interbody device. Ventura NanoMetalene, which has been commercially available since 2015, has expanded its size offerings to accommodate a larger range of posterior procedures and a wider variety of patient anatomies. These new sizes include additional lengths and oblique placement options with sagittally oriented lordosis. 
 
The Ventura interbody devices feature proprietary NanoMetalene surface technology. NanoMetalene describes a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK implant using a high-energy, low-temperature process referred to as atomic fusion deposition. It is designed to provide implants a bone-friendly titanium surface on endplates and throughout graft apertures, while retaining the benefits associated with traditional PEEK implants, such as biocompatibility, a modulus of elasticity similar to bone, and excellent radiographic visibility for post-operative imaging. 
 
Ali Chahlavi, M.D., a neurosurgeon practicing in Jacksonville, Fla. and an early adopter of NanoMetalene, commented, “NanoMetalene has been an integral part of my fusion procedures. These implants deliver the same surface characteristics of titanium while maintaining PEEK’s radiolucency for clear assessment of fusion post-operatively, which has not always been my experience with a full titanium device.” With respect to the new lordotic options, he said, “the additional lordosis will improve my ability to restore better natural alignment to my patients.”
 
SeaSpine’s entire portfolio of posterior lumbar NanoMetalene interbody devices is cleared for use with both autograft and allograft. Having the additional indication allows surgeons more bone grafting options, including using Ventura NanoMetalene with SeaSpine’s new line of allograft demineralized bone fiber products.
 
“NanoMetalene is a differentiated product in a market that has become increasingly competitive,” stated Troy Woolley, vice president of marketing. “The expansion of this technology coupled with our advanced orthobiologics demonstrates our commitment to provide complementary, cost-effective procedural solutions to surgeons, hospitals and patients.”